Stocks in play: Theratechnologies Inc.

Presented preclinical data that demonstrate the potential utility of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902) -- both as a single agent and in combination with other anticancer therapies -- in targeting tumors that express the sortilin (SORT1) receptor. The new data were presented in poster sessions at the 2023 annual meeting of the American Association for Cancer Research (AACR) in Orlando, Fla. Theratechnologies Inc. shares T.TH are trading up $0.05 at $1.30.

Read:

• Global Lithium Supply Under Pressure as South American Nations Discuss "Lithium OPEC"

• International Lithium Buyers Looking to South America to Fill Supply Gaps

• Race to Secure Critical EV Battery Metals Ahead of Chinese Dominance Fully Underway

• Help is on the Way as Rising Alzheimer’s Cases Highlight Urgency for New Treatments

• FDA’s Wave of Fast Track Designations Pushing Momentum in Healthcare Sector in 2023